ICU-acquired weakness (critical illness polyneuromyopathy)
Neuromuscular · Critical Care / ICU
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Diffuse, symmetrical, flaccid weakness developing during critical illness — critical illness polyneuropathy, myopathy, or both. Risk factors: sepsis/MODS, prolonged immobilisation, hyperglycaemia, corticosteroids and neuromuscular blockers (especially combined), prolonged ventilation. Presents as failure to wean and profound limb weakness with preserved facial movement.
Red flags
- Weakness with a sensory level or sphincter involvement is NOT ICU-acquired weakness — image the cord
- Rapidly ascending weakness with autonomic instability — treat as Guillain–Barré
Assessment
Investigations
- Clinical: MRC sum score <48/60 in an awake patient suggests significant weakness
- Exclude mimics: cord pathology (sensory level), Guillain–Barré (ascending, areflexic, autonomic signs), myasthenia (fatigability, ocular), electrolytes (K⁺, Mg²⁺, PO₄³⁻), drugs
- Nerve conduction/EMG and rarely muscle biopsy differentiate neuropathy from myopathy when recovery stalls
Management
- Prevent: treat sepsis aggressively, control glucose (6–10 mmol/L), minimise sedation and steroid/NMB exposure, and mobilise EARLY — physiotherapy is treatment, not garnish
- Daily sedation holds + spontaneous awakening enable participation in rehabilitation
- Optimise nutrition without overfeeding; replace phosphate/Mg²⁺/K⁺
- Expect and plan for prolonged weaning — pressure-support reduction with rest, and tracheostomy for comfort where extended
- Set expectations: recovery over weeks–months; some deficit can persist ≥1 year (post-intensive-care syndrome) — refer to follow-up rehabilitation
The commonest cause of failure to wean the recovering patient — prevent it from day 1 with light sedation and early movement.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.